These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis. Strunk RW; Gratz JC; Maserati R; Scheld WM Antimicrob Agents Chemother; 1985 Sep; 28(3):428-32. PubMed ID: 2934021 [TBL] [Abstract][Full Text] [Related]
3. [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa]. Liu MT; Sheng MY; Zhang Y; Li Y Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1427-31. PubMed ID: 21756818 [TBL] [Abstract][Full Text] [Related]
4. The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental Pseudomonas keratitis. Reidy JJ; Hobden JA; Hill JM; Forman K; O'Callaghan RJ Cornea; 1991 Jan; 10(1):25-8. PubMed ID: 1902152 [TBL] [Abstract][Full Text] [Related]
5. A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis. Bu P; Riske PS; Zaya NE; Carey R; Bouchard CS J Ocul Pharmacol Ther; 2007 Jun; 23(3):213-20. PubMed ID: 17593004 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of ciprofloxacin in animal models of infection: endocarditis, meningitis, and pneumonia. Sande MA; Brooks-Fournier RA; Gerberding JL Am J Med; 1987 Apr; 82(4A):63-6. PubMed ID: 3578331 [TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis. Lipman J; Allworth A; Wallis SC Clin Infect Dis; 2000 Nov; 31(5):1131-3. PubMed ID: 11073740 [TBL] [Abstract][Full Text] [Related]
8. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa. Rhee MK; Kowalski RP; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131 [TBL] [Abstract][Full Text] [Related]
9. Zymar (Gatifloxacin 0.3%) shows excellent Gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand White rabbit keratitis model. Mah FS; Romanowski EG; Kowalski RP; Yates KA; Gordon YJ Cornea; 2007 Jun; 26(5):585-8. PubMed ID: 17525656 [TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis. Johnson M; Miniter P; Andriole VT J Infect Dis; 1987 Apr; 155(4):783-8. PubMed ID: 3102631 [TBL] [Abstract][Full Text] [Related]
11. Penetration of aztreonam into cerebrospinal fluid and brain of noninfected rabbits and rabbits with experimental meningitis caused by Pseudomonas aeruginosa. Strausbaugh LJ; Bodem CR; Laun PR Antimicrob Agents Chemother; 1986 Nov; 30(5):701-4. PubMed ID: 3099641 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of ciprofloxacin alone and in combination with azlocillin in experimental endocarditis due to Pseudomonas aeruginosa. Thauvin C; Lecomte F; Le Boete I; Grise G; Lemeland JF Infection; 1989; 17(1):31-4. PubMed ID: 2493429 [TBL] [Abstract][Full Text] [Related]
14. The relative efficacies of tobramycin and ciprofloxacin against Pseudomonas aeruginosa in vitro and in normal and granulocytopenic mice. Hoogeterp JJ; Mattie H; Terporten P Infection; 1988; 16(1):58-62. PubMed ID: 3129373 [TBL] [Abstract][Full Text] [Related]
15. Comparison of four aminoglycoside antibiotics in the therapy of experimental E. coli meningitis. Strausbaugh LJ; Mandaleris CD; Sande MA J Lab Clin Med; 1977 Apr; 89(4):692-701. PubMed ID: 321713 [TBL] [Abstract][Full Text] [Related]
16. Treatment of Pseudomonas meningitis with ceftazidime with or without concurrent therapy. Rodriguez WJ; Khan WN; Cocchetto DM; Feris J; Puig JR; Akram S Pediatr Infect Dis J; 1990 Feb; 9(2):83-7. PubMed ID: 2179845 [TBL] [Abstract][Full Text] [Related]
17. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. Walsh CC; Landersdorfer CB; McIntosh MP; Peleg AY; Hirsch EB; Kirkpatrick CM; Bergen PJ J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778 [TBL] [Abstract][Full Text] [Related]
18. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis. Guzek JP; Chacko D; Kettering JD; Wessels IF; Aprecio RM Cornea; 1994 Nov; 13(6):500-4. PubMed ID: 7842708 [TBL] [Abstract][Full Text] [Related]
19. Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa. Norden CW; Shinners E J Infect Dis; 1985 Feb; 151(2):291-4. PubMed ID: 3155780 [TBL] [Abstract][Full Text] [Related]
20. The activity of ciprofloxacin against Pseudomonas aeruginosa in normal and granulocytopenic mice. Mattie H; Hoogeterp JJ; Terporten P Pharm Weekbl Sci; 1987 Dec; 9 Suppl():S26-9. PubMed ID: 3125518 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]